Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

17 Feb 2021

Abstract excerpt

Long-Term Follow-up of CAR T-Cell–Treated Lymphoma Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33596362
DOI: 10.1056/nejmc2030164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell TherapyPMID 33596362Read ↗

CAR T-Cell Therapy in Large B-Cell LymphomaSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphomaSemantic proximity Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaSemantic proximity Read ↗

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapseSemantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal B cell lymphomaSemantic proximity Read ↗

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity Read ↗

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read ↗

A CAR-T response prediction model for r/r B-NHL patients based on a T-cell subset nomogramSemantic proximity Read ↗

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.